Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Genetic mutations in ALL patients & implications for treatment decisions

Shawn Lee • 19 Aug 2021
SOHO 2021
Acute Lymphoblastic Leukemia Leukemia

Shawn Lee, MD, St. Jude Children’s Research Hospital, Memphis, TN, discusses the genetic alterations found in patients with acute lymphoblastic leukaemia (ALL) and how impacts treatment decisions. Dr Lee describes the different genetic subtypes of ALL and the categorization of favorable, intermediate, and high-risk groups. Dr Lee also explains the prevalence of the different subgroups among different races and the treatment approaches used, before commenting on the importance of subtyping on treatment protocol design in different countries. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

More from Shawn Lee

Disparities in outcomes for patients with ALL
0:48
Disparities in outcomes for patients with ALL
Shawn Lee • 19 Aug 2021
Genetic ancestry: the implications for biology and prognosis of childhood ALL
3:38
Genetic ancestry: the implications for biology and prognosis of childhood ALL
Shawn Lee • 19 Aug 2021

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals